1 Murren JR.Modulating multidrug resistance-can we target this therapy[ J] ? Clin Cancer Res, 2002; 8 : 633-5
2 Ambudkar SV, Dey S , Hrycyna CA , Ramachandra M , Pastan I, Gottesman MM .Biochemical , cellular, and pharmacological as- pects of the multidrug transporter[ J] . Annu Rev Pharmacol Toxi- col, 1999; 39 : 361-98
3 Zhang JT. The multi-structural feature of the multidrug resistance gene product P-glycoprotein:implications for its mechanism of action (hypothesis) [ J] .Mol Membr Biol, 2001, 18 : 145-52
4 Lin JH , Yamazaki M.Role of P-glycoprotein in pharmacokinetics -clinical implications[ J] . Clin Pharmacokinet, 2003 ; 42: 59-98
5 Loo TW, Bartlett MC , Clarke DM . Substrate-induced conforma- tional changesin the transmembrane segments of human P-glyco- protein.Direct evidence for the substrate-induced fit mechanism for drug binding[ J] . J Biol Chem, 2003; 278: 13603 -6
6 Loo TW, Clarke DM.Determining the dimensions of the drug- binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers[ J] .J Biol Chem , 2001 ; 276 : 36877-80
7 Rosenberg MF , Kamis AB, Callaghan R, Higgins CF, Ford RC . Three-dimensional structures of the mammalian multidrug resis- tance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding [ J] . J Biol Chem, 2003; 278 : 8294-9
8 Martin C , Berridge G, Higgins CF, Mistry P, Charlton P, Cal- laghan R. Communication between multiple drug binding sites on P-glycoprotein[ J] . Mol Pharmacol, 2000 ; 58: 624-32
9 Garrigues A, Loiseau N , Delaforge M, Ferte J, Garrigos M, Andre F, et al .Characterization of two pharmacophores on the multi- drug transporter P-glycoprotein[ J] .Mol Pharmacol, 2002;62: 1288 -98
10 Luker GD, Flagg TP, Sha Q, Luker KE , Pica CM , Nichols CG, et al .MDR1 P-glycoprotein reduces influx of substrates without affecting membrane potential[ J] . J Biol Chem , 2001 ; 276 : 49053 -60
11 Loo TW, Bartlett MC , Clarke DM.Drug binding in human P- glycoprotein causes conformational changes in both nucleotide- binding domains[ J] .J Biol Chem, 2003; 278 : 1575 -8
12 Loo TW, Bartlett MC, Clarke DM . Cross-linking of human mul- tidrug resistance P-gly coprotein by the substrate , tris-(2-male- imidoethyl)amine , is altered by ATP hydroly sis-evidence for ro- tation of a transmembrane helix [ J] .J Biol Chem , 2001 ; 276: 31800 -5
13 Sauna ZE, Ambudkar SV.Characterization of the catalytic cy- cle of ATP hydrolysis by human P-glycoprotein-the two ATP hydroly sis events in a single catalytic cy cle are kinetically simi- lar but affect different functional outcomes[ J] .J Biol Chem, 2001 ; 276: 11653-61
14 Berridge G, Walker JA, Callaghan R, Kerr ID. The nucleotide- binding domains of P-glycoprotein-functional symmetry in the isolated domain demonstrated by N-ethylmaleimide labeling[ J] . Eur J Biochem, 2003; 270 : 1483 -92
15 Mealey KL, Barhoumi R, Burghardt RC, Safe S , Kochevar DT.Doxy cycline induces expression of P-glycoprotein in MCF-7 breast carcinoma cells [ J] .Antimicrob Agents Chemother, 2002 ; 46: 3755-61
16 Brouillard F, Tondelier D, Edelman A, Baudouin-Legros M. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells [ J] . Cancer Res, 2001 ; 61: 1693-8
17 Kim RB.Drugs as P-glycoprotein substrates inhibitors, and in- ducers[ J] . Drug Metab Rev , 2002; 34: 47 -54
18 Yague E , Armesilla AL, Harrison G, Elliott J, Sardini A, Higgins CF, et al . P-glycoprotein (MDR1)expression in leuke- mic cells is regulated at two distinct steps, mRNA stabilization and translational initiation[ J] . J Biol Chem, 2003 ; 278: 10344 -52
19 Ding S, Chamberlain M, McLaren A, Goh L, Duncan I, Wolf CR. Cross-talk between signaling pathways and the multidrug re- sistant protein MDR-1[ J] . Br J Cancer, 2001; 85 : 1175 -84
20 Sakaeda T, Nakamura T, Hirai M, Kimura T, Wada A , Yagami T, et al .MDR1 up-regulated by apoptotic stimuli suppresses ap- optotic signaling[ J] . Pharm Res, 2002; 19 : 1323 -9
21 Cummins CL, Jacobsen W, Benet LZ .Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4[ J] .J Pharmacol Exp Ther, 2002 ; 300: 1036-45
22 Cummins CL, Salphati L, Reid MJ, Benet LZ.In vivo modu- lation of intestinal CYP3A metabolism by P-glycoprotein:studies using the rat single-pass intestinal perfusion model[ J] . J Phar- macol Exp Ther, 2003; 305: 306 -14
23 Baguley BC. Novel strategies for overcoming multidrug resistance in cancer[ J] . Biodrugs, 2002; 16 : 97-103
24 Batrakova EV, Li S , Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV .Mechanism of pluronic effect on P-glycopro- 中国临床药理学与治疗学 2006 Jan; 11(1) · 19 ·tein efflux system in blood-brain barrier:contributions of energy depletion and membrane fluidization [ J] .J Pharmacol Exp Ther, 2001 ; 299: 483-93
25 Lu P, Liu R, Sharom FJ. Drug transport by reconstituted P-gly- coprotein in proteoliposomes-effect of substrates and modulators, and dependence on bilayer phase state[ J] .Eur J Biochem , 2001; 268: 1687 -97
26 Ferte J .Analysis of the tangled relationships between P-glycop- rotein-mediated multidrug resistance and the lipid phase of the cell membrane[ J] . Eur J Biochem, 2000; 267: 277 -94
27 Regev R, Assaraf YG, Eytan GD.Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycop- rotein ATPase activity and modulates efflux from multidrug-resis- tant cells[ J] .Eur J Biochem , 1999; 259: 18 -24
28 Plo I, Lehne G, Beckstrom KJ, Maestre N, Bettaieb A, Laurent G, et al . Influence of ceramide metabolism on P-glycop- rotein function in immature acute myeloid leukemia KG1a cells [ J] .Mol Pharmacol, 2002; 62 : 304 -12
29 Newman MJ, Rodarte JC , Benbatoul KD, Romano SJ, Zhang C, Krane S , et al .Discovery and characterization of OC144- 093, a novel inhibitor of P-gly coprotein-mediated multidrug re- sistance[ J] .Cancer Res, 2000; 60: 2964-72
30 Paul i - Magnus C , von Richter O, Burk O, Ziegler A, Mettang T , Eichelbaum M, et al .Characterization of the major metabo- lites of Verapamil as substrates and inhibitors of P-glycoprotein [ J] . J Pharmacol Exp Ther, 2000; 293 : 376 -82
31 Wandel C , Kim RB, Guengerich FP, Wood AJ .Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycop- rotein and CYP3A in vitro[ J] . Drug Metab Dispos, 2000 ; 28: 895 -8
32 Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S , et al .Safety and efficacy of the multidrug resistance inhibitor incel (Biricodar;VX-710)in combination with paclita- xel for advanced breast cancer refractory to paclitaxel [ J] . Clin Cancer Res, 2002; 8 : 670-8
33 Choo EF, Leake B, Wandel C , Imamura H , Wood AJ, Wilkinson GR, et al . Pharmacological inhibition of P-glycopro- tein transport enhances the distribution of HIV-1 protease inhibi- tors into brain and testes[ J] .Drug Metab Dispos, 2000 ; 28: 655 -60
34 van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Es- kens FA, Brouwer E, et al . The orally administered P-glycopro- tein inhibitor R101933 does not alter the plasma pharmacokinet- ics of docetaxel [ J] . Clinl Cancer Res, 2000 : 1365-71
35 Mistry P, Stewart AJ, Dangerfield W, Okiji S , Liddle C , Bootle D, et al .In vitro and in vivo reversal of P-glycoprotein- mediated multidrug resistance by a novel potent modulator, XR9576[ J] .Cancer Res, 2001; 61 : 749 -58
36 Ekins S , Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB , et al .Three-dimensional quantitative structure-activity re- lationships of inhibitors of P-glycoprotein [ J] .Mol Pharmacol , 2002; 61 : 964-73
37 Ekins S , Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB , et al .Application of three-dimensional quantitative struc- ture-activity relationships of P-gly coprotein inhibitors and sub- strates[ J] . Mol Pharmacol, 2002 ; 61: 974-81
38 Stouch TR, Gudmundsson O.Progress in understanding the structure-activity relationships of P-glycoprotein [ J] .Adv Drug Deliv Rev , 2002 ; 54: 315-28
39 Wang EJ, Casciano CN, Clement RP, Johnson WW.In Vitro flow cytometry method to quantitatively assess inhibitors of P- glycoprotein[ J] . Drug Metab Dispos, 2000; 28 : 522-8
40 Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH , et al . In vitro substrate identification studiesfor P-glycopro- tein-mediated transport :species difference and predictability of in vivo results[ J] .J Pharmacol Exp Ther, 2001; 296: 723 -35
41 Patel VA, Dunn MJ, Sorokin A . Regulation of MDR-1 (P-gly- coprotein)by cyclooxygenase-2[ J] . J Biol Chem, 2002 ;277: 38915 -20
42 Veau C, Faivre L, Tardivel S, Soursac M , Banide H , Lacour B , et al .Effect of inteleukin-2 on intestinal P-glycoprotein ex- pression and functionality in mice[ J] .J Pharmacol Exp Ther, 2002 ; 302: 742-50
43 Thevenod F, Friedmann JM, Katsen AD, Hauser IA.Up-regu- lation of multidrug resistance P-glycoprotein via nuclear factor-B activation protects kidney proximal tubule cells from cadmium- and reactiveoxygen species-induced apoptosis[ J] .J Biol Chem, 2000 ;275: 1887-96
44 Wartenberg M , Ling FC, Schallenberg M, Baumer AT, Petrat K, Hescheler J, et al .Down-regulation of intrinsic P-glycopro- tein expression in multicellular prostate tumor spheroids by reac- tive oxygen species[ J] .J Biol Chem , 2001 ; 276: 17420-28
45 Yang JM , Vassil AD, Hait WN. Activation of phospholipase C induces the expression of the multidrug resistance (MDR1)gene through the Raf-MAPK Pathway[ J] .Mol Pharmacol, 2001; 60: 674 -80
46 Gill PK, Gescher A, Gant TW.Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes αand θ [ J] . Eur J Biochem, 2001; 268 : 4151-7
47 Castro AF, Horton JK, Vanoye CG, Altenberg GA.Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers[ J] .Biochem Pharmaco , 1999; 58: 1723 -33
48 da Rocha AB, Mans DR, Regner A, Schwartsmann G. Target- ing protein kinase C : -new therapeutic opportunities against high- grade malignant gliomas[ J] ? Oncologist , 2002; 7: 17 -33
49 Jin S , Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacety lase is mediated by NF- Y[ J] .Mol Cell Biol, 1998 ; 18: 74377-84
50 Xu D, Ye D, Fisher M , Juliano RL. Selective inhibition of P- glycoprotein expression in multidrug resistant tumor cells by a designed transcriptional regulator[ J] . J Pharmacol Exp Ther, 2002 ; 302: 963-71
51 Vilaboa NE , Galan A, Troyano A , de Blas E, Aller P. Regula- tion of multidrug resistance 1(MDR1) P-glycoprotein gene ex- pression and activity by hea t - shock transcription factor 1(HSF1) [ J] . J Biol Chem , 2000; 275: 24970-6
52 Chan JY, Chu AC, Fung KP. Inhibition of P-glycoprotein ex- pression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdr1) antisense RNA[ J] . Life Sci , 2000;67: 2117 -24
53 Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, Juliano RL.Antisense inhibition of P-glycoprotein expression using pep- tide-oligonucleotide conjugates[ J] .Biochem Pharmaco , 2000;
60 : 83-90 · 20 · Chin J Clin Pharmacol Ther 2006 Jan; 11(1)54 Bashir I, Sikora K, Foster CS. Generation of a monoclonal anti- body to P-glycoprotein peptides using tuberculin-PPD as a carrier [ J] . Virchows Arch , 1998 , 432: 279-87
55 Brady JM, Cherrington NJ, Hartley DP, Buist SC , Li N, et al .Tissue distribution and chemical induction of multiple drug resistance genesin rats[ J] . Drug Metab Dispos, 2002 ; 30: 838-
44 56 Lo YL. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial caco-2 cell layers and everted gut sacs of rats[ J] .Biochem Pharmacol , 2000; 60 : 1381 -90
57 Luciani F, Molinari A , Lozupone F, Calcabrini A, Lugini L, Stringaro A, et al .P-gly coprotein-actin association through ERM family proteins:a role in P-gly coprotein function in human cells of lymphoid origin[ J] .Blood , 2002; 99: 641 -8
58 Watts GS , Futscher BW, Isett R, Gleason-Guzman M , Kunkel MW, Salmon SE . cDNA microarray analysis of multiple defects in apoptosis signaling pathways [ J] . J Pharmacol Exp Ther, 2001; 299: 434 -41
59 Ruefli AA, Smyth MJ, Johnstone RW. HMBA induces activa- tion of a caspase-independent cell death pathway to overcome P- gly coprotein-mediated multidrug resistance[ J] .Blood , 2000 ; 95 : 2378-85
60 Johnstone RW, Tainton KM, Ruefli AA , Froelich CJ, Cerruti L, Jane SM, et al .P-glycoprotein does not protect cells against cytolysis induced by pore-forming proteins [ J] . J Biol Chem , 2001 ; 276: 16667-73
61 Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C , Nguyen L, Relling MV , et al .Altered expression of hepatic cytochromes p450 in mice deficient in one or more mdr1 genes[ J] .Mol Pharmaco , 2000; 57: 188 -97
62 Frank MH , Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM . Specific MDR1 P-glycoprotein blockade inhibits hu- man alloimmune T cell activation in vitro[ J] .J Immunol, 2001; 166 : 2451-9
63 Kondratov RV, Komarov PG, Becker Y, Ewenson A , Gudkov AV. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycopro- tein[ J] . Proc Natl Acad Sci USA, 2001 ; 98: 14078-83
64 Stephens RH , O' Neill CA, Bennett J, Humphrey M, Henry B , Rowland M, et al .Resolution of P-glycoprotein and non-P- glycoprotein effects on drug permeability using intestinal tissues from mdr1a(- -)mice [ J] .Br J Pharmaco , 2002 ; 135: 2038 -46
65 Batrakova EV, Li S , Elmquist WF , Miller DW, Alakhov VY, Kabanov AV. Mechanism of sensitization of MDR cancer cells by pluronic block copolymers:Selective energy depletion[ J] .Br J Cancer, 2001;85: 1987 -97
66 Shain KH, Dalton WS.Cell adhesion is a key determinant in de novo multidrug resistance(MDR):-new targets for the pre- vention of acquired MDR[ J] .Mol Cancer Ther, 2001: 69 -78 |
